SMARTO ONE

PreclinicalSmall molecule

MMei Han

SMARTO ONE is one of 5 small molecule programs targeting Neurodegenerative Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurodegenerative DiseaseActive, not recruiting

Neurodegenerative DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Neurodegenerative Disease

#DrugCompanyPhaseTrials

Nuplazid

AACADIA Pharmaceuticals Inc.

Approved

2 2

Namenda

AbbVie

Preclinical

1 3

Intropin

Pfizer

Preclinical

—4

Citicoline

UUniversity of Texas Southwestern Medical Center

SMARTO ONE

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurodegenerative Disease1 trial

Single Arm Clinical Trial of Small Molecule Natural Flavonoid Compounds for Intervention in Neurodegenerative Diseases

Unknown status·MMei Han·N/A·NCT05947409·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SMARTO ONE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SMARTO ONE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SMARTO ONE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mei Han company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMei Han

SMARTO ONE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neurodegenerative Disease1 trial

References

Drug Info

Quick Facts

Related News